Caredx comments on moldx publication of new billing and coding article

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the release of a billing article related to moldx molecular testing for solid organ allograft rejection that covers allosure® and allomap®. the billing article is effective march 31, 2023.
CDNA Ratings Summary
CDNA Quant Ranking